References
- Shafrin J, Lakdawalla D, Doshi J, et al. A strategy for value-based drug pricing under the inflation reduction act. Health Affairs Forefront. 2023.
- Gold M. Panel on cost-effectiveness in health and medicine. Med Care. 1996;34(12 Suppl):DS197–DS199.
- Academy of Managed Care Pharmacy. The AMCP format for formulary submissions: a format for submission of clinical and economic evidence in support of formulary consideration. Alexandria, VA: AMCP; 2016. https://www.amcp.org/sites/default/files/2019-03/AMCP-Format-V4.pdf.
- Institute for Clinical and Economic Review. ICER’s Impact Boston, MA: ICER; 2023. Available from: https://icer.org/who-we-are/history-impact/.
- Institute for Clinical and Economic Review. Unsupported price increase report: 2019 assessment. Boston, MA: ICER; 2019. http://icerorg.wpengine.com/wp-content/uploads/2020/10/ICER_UPI_Final_Report_and_Assessment_110619.pdf.
- Centers for Medicare & Medicaid Services. Medicare Drug Price Negotiation Program: selected drugs for initial price applicability year 2026. CMS [cited August 29, 2023]. Available from: https://www.cms.gov/files/document/fact-sheet-medicare-selected-drug-negotiation-list-ipay-2026.pdf.
- Centers for Medicare & Medicaid Services. Medicare drug price negotiation program: revised guidance, implementation of sections 1191–1198 of the social security act for initial price applicability year 2026. Baltimore, Maryland: CMS; 2023. https://www.cms.gov/files/document/revised-medicare-drug-price-negotiation-program-guidance-june-2023.pdf.
- United States House of Representatives. Inflation Reduction Act of 2022 [cited August 16, 2022]. Available from: https://www.congress.gov/117/plaws/publ169/PLAW-117publ169.pdf.
- Angelis A, Lange A, Kanavos P. Using health technology assessment to assess the value of new medicines: results of a systematic review and expert consultation across eight European countries. Eur J Health Econ. 2018;19(1):123–152. doi: 10.1007/s10198-017-0871-0.
- Abbas SM, Usmani A, Imran M. Willingness to pay and its role in health economics. J Bahria Uni Med Dent Coll. 2019;09(01):62–66. doi: 10.51985/JBUMDC2018120.
- Stobierski T. A beginner’s guide to value-based strategy Cambridge, MA2022. Available from: https://online.hbs.edu/blog/post/value-based-strategy.
- Shafrin J. Healthcare economist [Internet] 2008 [cited August 5, 2023]. Available from: https://www.healthcare-economist.com/2008/02/13/welfarists-vs-extra-welfarists/.
- Institute for Clinical and Economic Review. 2020-2023 value assessment framework. Boston, Massachusetts: ICER; 2020. https://icer.org/wp-content/uploads/2020/10/ICER_2020_2023_VAF_102220.pdf.
- Brouwer WBF, Culyer AJ, van Exel NJA, et al. Welfarism vs. extra-welfarism. J Health Econ. 2008;27(2):325–338. doi: 10.1016/j.jhealeco.2007.07.003.
- Moon S, Mariat S, Kamae I, et al. Defining the concept of fair pricing for medicines. BMJ. 2020;368:l4726. doi: 10.1136/bmj.l4726.